Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Cixutumumab Recombinant Human Monoclonal Antibody

Human Recombinant Monoclonal Antibody
Supplier: Invitrogen™ MA541876
This item is not returnable.
View return policy
Description
Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.
Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate. Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumor types.
Specifications
| Cixutumumab | |
| Recombinant Monoclonal | |
| Unconjugated | |
| IMC-A12; LY3012217 | |
| Human IGF1R/CD221. | |
| 100 μg | |
| Primary | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Liquid | |
| Chemical |
| ELISA, SDS-Page | |
| 3.28 mg/mL | |
| PBS with no preservative; pH 7.4 | |
| Human | |
| Protein A/G | |
| RUO | |
| Human | |
| Antibody | |
| IgG1 λ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction